NVO

$124.23

▲+3.72%

wb_incandescent Backtest

Stock

Novo Nordisk A/S Common Stock

Official Company Name: Novo Nordisk A/S

Stock Symbol: NVO

Stock Market: New York Stock Exchange - NYSE

Currency: United States dollar - USD

business Novo Nordisk Company Profile

NVO Stock Price - 1 Year Price Evolution & Moving Averages

1 Year Return

▲+73.02%

file_download

Daily closing prices, with moving averages and volumes - United States dollar (USD)
Moving averages:

  • EMA20
  • SMA50
  • SMA200

Company Description

Novo Nordisk is a global healthcare company involved in the research, development, manufacture, and marketing of pharmaceutical products. It operates through two segments: Diabetes and Obesity care, providing products for insulins, GLP-1, oral antidiabetic products, obesity, and other chronic diseases; and Biopharm, offering products for haemophilia, growth disorders, and hormone replacement therapy.

business Novo Nordisk Company Profile

NVO Stock Data

Open $122.80
High $124.43
Low $122.25
Close $124.23
Volume 5,559,600
Previous Close $119.77
1-Day Change 4.46
1-Year Change 52.43
Average Daily Volume 3,797,347
52-Week High $124.52
52-Week Low $69.45

NVO Stock References

warning

Disclaimer

All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!

Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.

Successful backtests on past data do not guarantee the future success of the strategy backtested, especially as backtest overfitting may occur: when the price of a stock may fit particularly well a given trading strategy over a given period, but not necessarily outside of that period. Besides, backtests do not account for exact market conditions and may yield significantly different results in real trading practice (fees, slippage...).

Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.

Please conduct your own due diligence to verify insights.